BioMed Realty Trust (BioMed Realty Trust) COGS-to-Revenue : 0.36 (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is BioMed Realty Trust COGS-to-Revenue?

BioMed Realty Trust's Cost of Goods Sold for the three months ended in Sep. 2015 was $62.1 Mil. Its Revenue for the three months ended in Sep. 2015 was $174.3 Mil.

BioMed Realty Trust's COGS to Revenue for the three months ended in Sep. 2015 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BioMed Realty Trust's Gross Margin % for the three months ended in Sep. 2015 was 64.40%.

BioMed Realty Trust COGS-to-Revenue Historical Data

The historical data trend for BioMed Realty Trust's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMed Realty Trust COGS-to-Revenue Chart

BioMed Realty Trust Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

COGS-to-Revenue

Get a 7-Day Free Trial

0.29

0.32

BioMed Realty Trust Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
COGS-to-Revenue	Get a 7-Day Free Trial															0.33	0.32	0.33	0.35	0.36

BioMed Realty Trust COGS-to-Revenue Calculation

BioMed Realty Trust's COGS to Revenue for the fiscal year that ended in Dec. 2014 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	214.502	/	674.609
	=	0.32

BioMed Realty Trust's COGS to Revenue for the quarter that ended in Sep. 2015 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	62.069	/	174.348
	=	0.36

BioMed Realty Trust (NYSE:BMR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BioMed Realty Trust's Gross Margin % for the three months ended in Sep. 2015 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	62.069 / 174.348
	=	64.40 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BioMed Realty Trust COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioMed Realty Trust's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMed Realty Trust (BioMed Realty Trust) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » BioMed Realty Trust Inc (NYSE:BMR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.biomedrealty.com

BioMed Realty Trust Inc, a Maryland corporation was formed on April 30, 2004 and commenced operations on August 11, 2004, after completing its initial public offering. The Company operates as a self-administered and self-managed real estate investment trust focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry mainly through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership Its tenants mainly include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/ New Jersey. The Company faces competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. The Company's properties are subject to various laws, ordinances and regulations, including regulations relating to common areas.

Executives

Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Brody William R Md Phd	director	MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Janice L. Sears	director	1100 PARK PLACE, SUITE 200, SAN MATEO CA 94403
Alan D Gold	director, officer: Chairman, President and CEO	17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Gary A Kreitzer	director, officer: Exec VP and Assistant Sec	17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Margaret Faye Wilson	director	12836 LUNADA PLACE, SAN DIEGO CA 92128
Griffin R Kent Jr	officer: President and COO	5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Richard I Gilchrist	director	5950 SHERRY LANE, SUITE 700, DALLAS TX 75225